Loading
ZC
Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.) Stock: price and insider trades · Canada
Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.): what insiders have been doing
Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.) is a listed company. Its directors and officers file their transactions with SEDI. Over the twelve months to 23 October 2026, 6 filings were filed, from 3 insiders.
Not one open-market sale was filed. On the buying side, 1 insider reported 3 purchases totalling €17k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 1 senior executive among the declarants. One trade stands out by size: a purchase of €8,959 from Klass, Russell Kevin, disclosed on 14 November 2025.
The last purchase on record was published on 14 November 2025, which is 343 days ago. The median gap between a trade and its publication by SEDI is 2 days. That lag is the time during which only the insider knows about the trade.
Compared with its exchange (2,472 companies, median 13 filings), a count of 6 filings is below the norm. Over the whole record (from 2021), the tally stands at 56 purchases and 9 sales.
Source: insider filings from SEDI. Past trades are no guide to future returns.
Insider Decl.
95
Thresholds
n/a
Buy Volume
€629,605
56 ops. · all time
Sell Volume
€2M
9 ops. · all time
Who traded when
BuySaleRussell Kevin Klass12 buys
Johnny Powers7 buys
Jeffrey Mark Rowe6 buys
Larry C. Heaton5 buys
Tony Blair4 buys
Christopher MacLeod1 buy
+2 other insiders
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 7 August 2026
Declarations95 total
500,000 shares@ CA$0.09100.0% of flowOptionsTSXSEDI:4761477
250,000 shares@ CA$0.09100.0% of flowOptionsTSXSEDI:4761470
250,000 shares@ CA$0.09100.0% of flowOptionsTSXSEDI:4761466
150,000 shares@ CA$0.09729.5% of flowCommon SharesTSXSEDI:4605718
Canonical exit: 11 Feb 2026 (T+90)
120,000 shares@ CA$0.09823.9% of flowCommon SharesTSXSEDI:4604143
Canonical exit: 8 Feb 2026 (T+90)
5,000 shares@ CA$0.0951.0% of flowCommon SharesTSXSEDI:4603991
Canonical exit: 5 Feb 2026 (T+90)
60,723 shares@ CA$0.040.7% of flowCommon SharesTSXSEDI:4560423
Canonical exit: 9 Nov 2025 (T+90)
745,341 shares@ CA$0.048.6% of flowCommon SharesTSXSEDI:4560425
Canonical exit: 10 Nov 2025 (T+90)
250,000 shares@ CA$0.042.9% of flowCommon SharesTSXSEDI:4560424
Canonical exit: 10 Nov 2025 (T+90)
250,000 shares@ CA$0.042.9% of flowCommon SharesTSXSEDI:4559911
Canonical exit: 9 Nov 2025 (T+90)
500,000 shares@ CA$0.045.8% of flowCommon SharesTSXSEDI:4559908
Canonical exit: 6 Nov 2025 (T+90)
250,000 shares@ CA$0.0382.8% of flowCommon SharesTSXSEDI:4559909
Canonical exit: 9 Nov 2025 (T+90)
36,250 shares@ CA$0.0492.3% of flowCommon SharesTSXSEDI:4514662
Canonical exit: 19 Aug 2025 (T+90)
63,750 shares@ CA$0.054.0% of flowCommon SharesTSXSEDI:4514665
Canonical exit: 19 Aug 2025 (T+90)
104,300 shares@ CA$0.04818.7% of flowCommon SharesTSXSEDI:4514183
Canonical exit: 17 Aug 2025 (T+90)
500,000 shares@ CA$0.0461.2% of flowCommon SharesTSXSEDI:4514181
Canonical exit: 17 Aug 2025 (T+90)
100,000 sharesCommon SharesTSXSEDI:4481861
175,000 sharesCommon SharesTSXSEDI:4481865
100,000 sharesCommon SharesTSXSEDI:4481860
Common SharesTSXSEDI:4481778
Common SharesTSXSEDI:4481776
175,000 sharesCommon SharesTSXSEDI:4481864
8,000 shares@ CA$1.048.6% of flowCommon SharesTSXSEDI:4481779
Canonical exit: 16 Jan 2017 (T+90)
68,000 shares@ CA$0.0674.3% of flowCommon SharesTSXSEDI:4481868
Canonical exit: 15 Jun 2025 (T+90)
500,000 shares@ CA$0.06430.4% of flowCommon SharesTSXSEDI:4481866
Canonical exit: 15 Jun 2025 (T+90)
25 of 95 declarations
About Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.)
Zomedica Corp. is a biotechnology company focused on developing diagnostic and therapeutic products for companion animals. It aims to improve animal health through innovative solutions.
